Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease

Abstract Nalfurafine hydrochloride, a selective κ-opioid receptor agonist has been approved for pruritus in patients with chronic liver disease. However, not all patients respond to nalfurafine hydrochloride. The aim of this study was to clarify the efficacy of nalfurafine hydrochloride. The subject...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tadamichi Kawano, Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Hidenori Toyoda, Koichi Takaguchi, Joji Tani, Asahiro Morishita, Atsushi Hiraoka, Shigeru Mikami, Toru Ishikawa, Hironao Okubo, Tsunamasa Watanabe, Tomomi Okubo, Taeang Arai, Korenobu Hayama, Norio Itokawa, Chisa Kondo, Katsuhiko Iwakiri
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Portfolio 2022-05-01
Colecção:Scientific Reports
Acesso em linha:https://doi.org/10.1038/s41598-022-11431-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados